Hard to Treat Diseases (HTDS) Plans a Share Buyback Program
As the company and its investors had been concerned with the company's share price being grossly undervalued, the company sees this as a great opportunity to shore up the float with a commencement of a share buyback program.
Neither the company nor its IR will comment on this topic further. The company will announce the exact numbers as soon as this is beneficially advantageous to itself and its shareholders.
HTDS management is well positioned to complete this task with cash flows from the sale of some of its disposed assets.
In other company news, the company has retained a California law firm to assist it in resolving any issues with Pink Sheets regarding the "skull and bones" icon on HTDS security and the naked short selling which effected the HTDS in the past, which now appear to be under check.
The company reminds its shareholders and followers to monitor PinkSheets.com Filing section and also our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/ for non newsworthy corporate updates.
For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link http://www.minamargroup.net/helpdesk.
Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and the remedies available to you as an individual investor.
Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact firstname.lastname@example.org; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
You May Also Like